Previous studies have shown that ALA alleviates the motor deficits in Parkinson’s disease (PD) models by regulating iron metabolism, including the upregulation of ferritin heavy chain (FTH1) and ferroportin (FPN), as well as the downregulation of divalent metal transporter 1 (DMT1). This evidence concerns the gene SLC40A1 and Parkinson disease.